Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 Jun 2:16:1602527.
doi: 10.3389/fimmu.2025.1602527. eCollection 2025.

IFN-γ gene polymorphisms +874 T/A and +2109 A/G are associated with the serofast state after early syphilis treatment: a prospective observational study

Affiliations
Observational Study

IFN-γ gene polymorphisms +874 T/A and +2109 A/G are associated with the serofast state after early syphilis treatment: a prospective observational study

Konrad Kaminiów et al. Front Immunol. .

Abstract

Background: In approximately 20% of patients with early syphilis, the classical serological response pattern is absent following treatment. They experience a serofast state, which manifests as less than a 4-fold decline in non-treponemal titres, without any clinical signs of treatment failure or reinfection. The effectiveness of the immune defense against T. pallidum, as well as its potential failure and the occurrence of the serofast state, depends on the Th1 cellular response, including cytokines such as IFN-γ. The aim of this prospective observational study was to investigate the impact of IFN-γ gene polymorphisms on the occurrence of the serofast state.

Materials and methods: A cohort of 97 patients with early syphilis (73.2% secondary syphilis, 26.8% early latent syphilis) and 50 healthy volunteers were enrolled. Two single nucleotide polymorphisms (SNPs) in the IFN-γ gene promoter region, +874 T>A (rs2430561) and +2109 A>G (rs1861494), were analyzed. Serum IFN-γ levels were measured at baseline, prior to treatment. Patients were stratified into serofast (n=18) and serologically cured (n=79) groups.

Results: Serofast patients exhibited significantly lower baseline serum IFN-γ levels compared to the serologically cured group (p=0.01). All healthy subjects had IFN-γ levels below the detection limit. Analysis of IFN-γ gene polymorphisms revealed a significant association with treatment outcomes. The +874 AA and +2109 GG genotypes, associated with low IFN-γ production, were significantly more frequent in serofast patients (p=0.0004 and p=0.002, respectively), with odds ratios (OR) of 7.1 (95% CI: 2.2-23.2) and 5.5 (95% CI: 1.8-17.3), respectively. Additionally, carriers of the +874A/+2109G haplotype were significantly more likely to remain serofast (OR 4.4, p=0.01). Conversely, the +874 TT and +2109 AA genotypes, associated with high IFN-γ production, were significantly linked to serological cure (OR 4.4, p=0.03; OR 4.4, p=0.01). Similarly, the +874T/+2109A haplotype was strongly associated with serological cure (OR 17.9, p<0.0001).

Discussion: Distinct IFN-γ polymorphisms and haplotypes are associated with serological outcomes in syphilis. The +874 T>A and +2109 A>G variants influence IFN-γ levels, potentially modulating the immune response and serological recovery. These findings suggest a genetic predisposition underlying serofast syphilis and underscore the importance of personalized approaches in its management.

Keywords: +2109 A/G; +874 T/A; IFN-γ; SNP; polymorphism; serofast state; syphilis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Serum IFN-γ levels in patients with syphilis according to IFN-γ gene polymorphisms.
Figure 2
Figure 2
IFN-γ gene polymorphisms with marked variants analyzed in this study.
Figure 3
Figure 3
Hypothetical mechanism linking IFN-γ gene polymorphisms to serofast state after syphilis treatment.

Similar articles

References

    1. Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC) . Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. (2010) 59:1–110. - PubMed
    1. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. (2015) 64:1–137. - PMC - PubMed
    1. Pastuszczak M, Gozdzialska A, Jakiela B, Obtulowicz A, Jaskiewicz J, Wojas-Pelc A. Robust pro-inflammatory immune response is associated with serological cure in patients with syphilis: an observational study. Sex Transm Infect. (2017) 93:11–4. doi: 10.1136/sextrans-2016-052681 - DOI - PubMed
    1. Pastuszczak M, Jakiela B, Wojas-Pelc A. Association of interleukin-10 promoter polymorphisms with serofast state after syphilis treatment. Sex Transm Infect. (2019) 95:163–8. doi: 10.1136/sextrans-2018-053753 - DOI - PubMed
    1. Zhang RC, Zheng NN, Zhong LS. Association of TNF-α -308 G>A gene polymorphism with serofast in patients with syphilis. Australas J Dermatol. (2021) 62:e294–6. doi: 10.1111/ajd.13481 - DOI - PubMed

Publication types